Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors

Pain

Volumn 97, Issue 1-2, 2002, Pages 11-21

  Farquhar Smith, W Paul ^a   Jaggar, Sian I ^a   Rice, Andrew S C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anandamide; Fos; Inflammation; Pain; Palmitoylethanolamide; Urinary bladder

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; PALMIDROL; PROTEIN C FOS; RECEPTOR SUBTYPE; RECOMBINANT NERVE GROWTH FACTOR; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; AUTONOMIC HYPERREFLEXIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; HYPERALGESIA; IMMEDIATE EARLY GENE; INFLAMMATION; LUMBAR SPINAL CORD; MICTURITION REFLEX; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANIMALS; ARACHIDONIC ACIDS; BORNANES; CANNABINOIDS; ENDOCANNABINOIDS; FEMALE; HYPERALGESIA; NERVE GROWTH FACTOR; PALMITIC ACIDS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS C-FOS; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; REFLEX, ABNORMAL; SPINAL CORD; URINARY BLADDER; VISCERAL AFFERENTS;

EID: 0036276727     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(01)00419-5     Document Type: Article

References (81)

1. Molecular neurobiology of the cannabinoid receptor
2. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
3. Intraplantar injection of nerve growth factor into the rat hind paw: Local edema and effects on thermal nociceptive threshold
4. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
5. Nerve growth factor (NGF) differentially regulates the chemosensitivity of adult rat cultured sensory neurons
6. Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat
7. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonylglycerol in mouse neuroblastoma cells
8. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain
9. 1 receptor is localised predominantly on N52 positive neurons within the dorsal root ganglion
10. Control of pain initiation by endogenous cannabinoids
11. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide
12. Molecular characterisation of an enzyme that degrades fatty acid amides
13. Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process
14. Determination and characterization of a cannabinoid receptor in rat brain
15. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
16. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
17. Rapid inhibition of bladder but not uterine motility by CB1 receptor agonist WIN55,212-2 in rats
18. Sensitisation of visceral afferents by nerve growth factor in the adult rat
19. C.fos induction in a rat model of cystitis: Role of NGF
20. The role of nerve growth factor in a model of visceral inflammation
21. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: Evidence for a regulatory function of nerve growth factor in vivo
22. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
23. 1 receptor expression in rat spinal cord
24. Palmitoylethanolamide (PEA) attenuates NGF-induced hyperalgesia by reducing neutrophil accumulation via CB2-like receptors
25. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
26. In vivo NGF deprivation reduced SNS expression and TTX-R sodium currents in IB4-negative neurons
27. Identification of genes differentially expressed by nerve growth factor and neurotrophin-3 dependent sensory neurones
28. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
29. 2 receptors
30. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
31. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
32. Localisation of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridisation study
33. Cannabinoid receptors undergo axonal flow in sensory nerves
34. The cannabinoid receptor: Biochemical, anatomical and behavioural characterisation
35. Induction of c-fos like protein in spinal cord neurons following sensory stimulation
36. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
37. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat bladder
38. Inflammation of the rat urinary bladder is associated with a referred hyperalgesia which is NGF dependent
39. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors
40. Mast cells synthesize, store and release nerve growth factor
41. Activation of bladder mast cells in interstitial cystitis
42. Nerve growth factor: From neurotrophin to neurokine
43. Nerve growth factor and nociception
44. Peripheral and central mechanisms of NGF-induced hyperalgesia
45. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis
46. Nerve growth factor treatment increases stimulus evoked release of sensory neuropeptides in the rat spinal cord
47. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
48. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
49. Neuronal and behavioural consequences of chemical inflammation of rat urinary bladder
50. A model for the study of visceral pain states: Chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals
51. Changes in the afferent innervation of the inflamed urinary bladder
52. Silent afferents and visceral pain
53. Expression and coexpression of trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets
54. Suppression of nerve growth factor trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation
55. Spinal cord cytoarchitecture
56. Molecular characterisation of a peripheral receptor for cannabinoids
57. A psychophysical study of discomfort produced by repeated filling of the urinary bladder
58. Human mast cells express functional trkA and are a source of nerve growth factor
59. Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder
60. Differences in expression of oligosaccharides, neuropeptides, carbonic anhydrase and neurofilament in rat primary afferent neurons retrogradely labelled via skin, muscle or visceral nerves
61. Endocannabinoids: A new class of vasoactive substances
62. Topical spinal administration of a nitric oxide synthase inhibitor prevents the hyper-reflexia associated with a rat model of persistent visceral pain
63. Recent developments in the pathophysiology of acute pain
64. Local neuro-immune interactions in visceral hyperalgesia: Bradykinin, neurotrophins and cannabinoids
65. Cannabinoids and pain
66. Pre-emptive intrathecal administration of an NMDA receptor antagonist (AP-5) prevents hyper-reflexia in a model of persistent visceral pain
67. Characteristics of nerve growth factor induced hyperalgesia in adult rats: Dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activity
68. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor
69. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands
70. Activation of human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase
71. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
72. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat
73. A second endogenous cannabinoid that modulates long-term potentiation
74. Biphasic effects of anandamide
75. Local injection of nerve growth factor (NGF) triggers degrannulation of mast cells in rat paw
76. Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist
77. Immunohistochemical distribution of cannabinoid receptors in the rat central nervous system
78. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
79. Sodium channels and pain
80. The biodisposition and metabolism of anandamide in mice